All News

EULAR19.abstract.jpg (keep)

Featured Abstracts from Industry at EULAR 2021

Jack Cush, MD

Many great presentations this week at EULAR 2021 will feature industry sponsored clinical trials and reports.  Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.

Read Article
Feet, foot

Foot Pain Commonly Overlooked in RA

MedPage Today

Foot pain is a common but underappreciated symptom of rheumatoid arthritis (RA) and can be associated with worse disease, European researchers found.

Read Article
RheumNow Podcast square

RheumNow Podcast – Heart, Lung & Liver (5.28.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
Vaccine2.jpg (keep)

Methotrexate Impairs COVID Vax Response

MedPage Today

One-third of patients with immune-mediated inflammatory diseases being treated with methotrexate showed attenuated responses to the COVID-19 vaccine, researchers reported.

Read Article
knee.surgery.jpg (keep)

Efficacy of 6 Weeks Antibiotics with Prosthetic Joint Infections

Jack Cush, MD

The NEJM has published the results of a French multicenter study showing that prosthetic joint infections can be successfully managed with 6 weeks of antibiotic therapy; this was noninferior and had better outcomes compared to 12 weeks of antibiotic therapy.

Read Article
Yes more lab abnormalities in #Upadactinib vs #Adalimumab in RA RCTs including cytopenias, transaminitis but not creatinine @RheumNow @eular_org #EULAR2021 but no diff in treatmt emergent Adverse events abst OP0128 Yes do labs when on #Upadacitinib https://t.co/5ypKGxuE3U https://t.co/XRjr0gDnIT

Links:

Janet Pope Janetbirdope ( View Tweet)
Do you really needs to follow labs for pts on #JAKi ? @eular_org #EULAR2021 OP0128 studied 4.5 years in #upadacitinb 6 RCTs in RA. More grade3 or 4 anemia, low lymph, neutrophils & ⬆️

Janet Pope Janetbirdope ( View Tweet)

Potential rheum board question... True or False? MUC5B is a promoter variant that can increase the risk for ILD in RA Dr. A Palomaki - winner of #EULAR 2021 Abstr award #OP0007 @RheumNow https://t.co/6xKHgXSJ29
k dao KDAO2011 ( View Tweet)
ILD in RA is a killer! @eular_org abst OP0099 Admin day from France claims database. ILD was clinically dx in 2.5% & had 3X mortality. Low prevalence compared to some studies of 6% so maybe worst cases but Impt cause of excess death in RA @RheumNow @eular_org @jeffsparks https://t.co/mPfpPSHxsd
Janet Pope Janetbirdope ( View Tweet)
MUC5B variant gene in 5634 RA pts had 2X ⬆️ risk of RA ILD - same gene as in IPF. Clinical relevance is unknown but could it result in a novel Rx pathway? ? Effect of sex & smoking @RheumNow @eular_org abst OP0007 #EULAR2021 https://t.co/8XpKjPFfUX
Janet Pope Janetbirdope ( View Tweet)
To clot or NOT? Real world data usually show no ⬆️ VTE in RA with #Jaki compares to other advanced therapies. Diff from high CV risk pts in Oral Surveillance where Tofacitinib had higher VTE vs TNFi @AbbVie symposium @eular_org #EULAR2021 @RheumNow Hard to reconcile diff risk. https://t.co/AWY2zZPSIb
Janet Pope Janetbirdope ( View Tweet)
Andrew Ostor @AbbVie symposium @eular_org presented HZ vaccines are safe in RA pts with #JAKi but with Recombinant HZ vaccine humeral response - 75% in RA pts in JAKi vs 100% controls. So should we hold JAKi with Shringix & if so for 1 or 2 wks? #EULAR2021 @RheumNow https://t.co/wVOFMa9fLm
Janet Pope Janetbirdope ( View Tweet)
Lifetime risk of HZ is 30%! ⬆️ in pts with immune diseases or immunesuppression. All #JAKI ⬆️ risk maybe doubling but NNH & NNT give context. UPA Rx in active RA -20 more pts in remission vs 1 excess HZ if comparing UPA to ADA in RA @RheumNow #EULAR2021 AbbVie symposium https://t.co/14i0IsIpzs
Janet Pope Janetbirdope ( View Tweet)
Hands-Down Rheumatology - Swollen Hands In Rheumatoid Arthritis - could be from synovitis, tenosynovitis, edema, effusion, bony hypertrophy, nodules, secondary OA. https://t.co/dRCMzgdHqf

Links:

Dr. John Cush RheumNow ( View Tweet)

News: Triple DMARD Therapy Bested by Biologics in Swedish Registry The Swedish Register compared outcomes of 1502 RA patients initiating either biologics plus MTX or triple therapy and showed similar rates of sustained remission. https://t.co/7JJxGF1tHz https://t.co/ht6kAsJkb9

Links:

Dr. John Cush RheumNow ( View Tweet)
News: EULAR Guidelines on Intraarticular Therapy EULAR has published evidence-based recommendations on the use of intra-articular therapies (IAT) based on the literature review and recommendations of a multidisciplinary international task force. https://t.co/Z6vC0x9zY1 https://t.co/gVCWMIJxtu

Links:

Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study RA and PFTs, shows among 2,008 cases, RA was assoc w/ increased odds of restrictive (OR 1.36) & obstructive patterns (OR 1.21) not explained by confounders like smoking. RA had lower predicted FEV1, FVC, FEV1/FVC https://t.co/cVxatLQCG4

Links:

Dr. John Cush RheumNow ( View Tweet)

Unable to attend the Tuesday Night Rheumatology on RA and vaccines? Watch the replay below. https://t.co/hUFTjDAnsg https://t.co/ywCRjqg1To

Links:

Dr. John Cush RheumNow ( View Tweet)
Virtual DDW meeting this wk reports claims data comparing IBD to IBD with RA - IBD alone vs IBD w/ RA dx w/ more depression (21% vs 84%), anxiety (20% vs 47%). IBD w/ RA had more depression (OR 7.2); anxiety (OR, 1.25;) or both (OR, 2.3) https://t.co/B78xcJw584

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: CV Risk Decreased with Certain DMARDs in Rheumatoid Arthritis A large prospective cohort study examined the comparative risks of CVD in patients with RA and found that, MTX, ABA & TNFi use were associated w/ a decreased risk of CV events. https://t.co/uQbtB76Hgy https://t.co/ftc5ys9C58

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×